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Abstract
Background: Podoplanin expression is attracting interest as a marker for cancer diagnosis and prognosis. We
therefore investigated the expression pattern and clinical significance of podoplanin during the development and
progression of laryngeal carcinomas.
Results: Podoplanin expression was determined by immunohistochemistry in paraffin-embedded tissue specimens
from 84 patients with laryngeal premalignancies and 53 patients with laryngeal squamous cell carcinomas. We
found podoplanin expression extending from the basal to the suprabasal layer of the epithelium in 37 (44%) of 84
dysplastic lesions, whereas normal epithelium showed negligible expression. Patients carrying podoplanin-positive
lesions had a higher laryngeal cancer incidence than those with negative expression reaching borderline statistical
significance (51% versus 30%, P = 0.071). Podoplanin expression in laryngeal carcinomas exhibited two distinct
patterns. 20 (38%) cases showed diffuse expression in most tumour cells and 33 (62%) focal expression at the
proliferating periphery of tumour nests. High podoplanin expression was inversely correlated with T classification
(P = 0.033), disease stage (P = 0.006), and pathological grade (P = 0.04). There was a trend, although not significant,
towards reduced disease-specific survival for patients with low podoplanin levels (P = 0.31) and diffuse expression
pattern (P = 0.08).
Conclusions: Podoplanin expression increases in the early stages of laryngeal tumourigenesis and it seems to be
associated with a higher laryngeal cancer risk. Podoplanin expression in laryngeal squamous cell carcinomas,
however, diminishes during tumour progression. Taken together, these data support a role for podoplanin
expression in the initiation but not in the progression of laryngeal cancers.
Background
Head and neck squamous cell carcinoma (HNSCC) is the
fifth most common cancer worldwide. Although in most
studies HNSCC is considered as a single type of carci-
noma, important differences in the clinical and biological
behaviour have been observed depending on the location
of the tumours (i. e. oral cavity, oropharynx, hypopharynx
and larynx). Patients with HNSCC have benefited greatly
from the latest advances in surgical techniques, radiation
therapy and chemotherapy. However, despite the
advancements in local control and overall quality-of-life
achieved with the use of combined modality therapies,
the survival rates for HNSCC have not improved signifi-
cantly over the past two decades [1]. Hence, novel meth-
ods of cancer detection and prognostication need to be
developed. Recent advances in genomic and basic
research have increased our understanding of the mole-
cular processes governing tumour formation and pro-
gression. HNSCC is a heterogeneous disease involving
dysregulation of multiple pathways linked to cellular dif-
ferentiation, cell cycle control, apoptosis, angiogenesis,
and metastasis [2]. Thus, much work is focused on the
identification of better biologic and molecular factors
that may serve as prognostic and predictive markers [3].
Human podoplanin is a 38-kDa mucin-type trans-
membrane glycoprotein consisting of 162 amino acids.
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podocytes [4], skeletal muscle, placenta, lung and heart
[5], in myofibroblasts of the breast and salivary glands,
in osteoblasts and mesothelial cells [6]. Occasionally,
focal expression of podoplanin can be found in circum-
scribed areas of the basal layer of the human epidermis
[7]. As podoplanin is expressed on lymphatic but not on
blood vessel endothelium, it has been widely used as a
specific marker for lymphatic endothelial cells and lym-
phangiogenesis in many species [4], including HNSCC
[8]
The expression of podoplanin is up-regulated in a
number of different human cancers, including squamous
cell carcinoma of the oral cavity, the lung, the cervix,
the oesophagus, and the skin, in dysgerminomas of the
ovary and granulosa cell tumours, in mesothelioma, and
in many tumours of the central nervous system (CNS)
[5,7,9-12]). In addition, recent experimental results have
demonstrated that podoplanin mediates a pathway lead-
ing to collective cell migration and invasion in vivo and
in vitro [12].
The expression of podoplanin in human cancers and
its relationship with tumour invasion raises the possibi-
lity that podoplanin expression could be used as a bio-
marker for diagnosis and prognosis. Supporting this
notion, podoplanin has been identified as a marker of
malignant transformation and poor prognosis in oral
cancer [13,14]. Since HNSCC may behave differently
depending on the tumour site, in this work we analysed
podoplanin expression in a series of squamous cell car-
cinomas and premalignant lesions of the larynx to ascer-
tain the role of podoplanin in both malignant
transformation and tumour progression and its clinical
significance in laryngeal cancer.
Methods
Patients and Tissue Specimens
Surgical tissue specimens from 84 patients with prema-
lignant lesions of the larynx and 53 patients with laryn-
geal squamous cell carcinomas who underwent surgical
treatment at the Hospital Universitario Central de
Asturias between 1996 and 2004 were retrospectively
collected, following institutional review board guidelines.
Informed consent was obtained from each patient.
Representative tissue sections were obtained from archi-
val, paraffin-embedded blocks and the histological diag-
nosis was confirmed by an experienced pathologist (M.
F.F.). The sections were selected for study as follows: In
premalignant lesions, the entire lesion was included in
one block and therefore the section used for histological
diagnosis was subsequently stained and evaluated. In
carcinomas, one representative section from the middle
of the tumour that also included the tumour border
(containing interfaces between the tumour nests and
stroma) and normal adjacent epithelium was selected
for staining.
Premalignant lesions were classified into the categories
of mild, moderate or severe dysplasia following the
WHO classification [15]. Fourteen (17%) lesions were
classified as mild dysplasia, 26 (31%) as moderate dyspla-
sia, and 44 (52%) as severe dysplasia/carcinoma “in situ”
(CIS). All patients were men, with a mean age of 64 years
(range 36-83 years). All of them were smokers, and 43
were also habitual alcohol drinkers. The patients with a
diagnosis of premalignant lesion and cancer within the
next six months were excluded from the study. All
patients were treated by excisional biopsy using stripping
microflap excision with cold instruments. A complete
macroscopic exeresis of the lesion was performed in all
cases, but the microscopic margins were not addressed.
Patients were followed-up for a minimum of 60 months
or until progression to malignancy occurs.
All patients with laryngeal squamous cell carcinoma
included in this study were surgically treated. All had a
single primary tumour, microscopically clear surgical
margins and received no treatment prior to surgery. A
total of 14 (26%) patients received post-operative radio-
therapy (this was administered to stage IV patients). All
but one of the patients were male, the mean age was 63
years (range 33 to 86 years). All of them were smokers
and 45 were also habitual alcohol drinkers. The charac-
teristics of the patients studied and the clinico-patholo-
gical features of their tumours are shown in Table 1.
The stage of the disease was determined after the surgi-
cal resection of the tumour according to the Tumor,
Lymph Node, Metastases TNM system of the Interna-
tional Union Against Cancer (6th edition). The histolo-
gical grade was determined according to the degree of
differentiation of the tumour (Broders’ classification).
Patients were followed up for at least 36 months.
Immunohistochemistry
The formalin-fixed, paraffin-embedded tissues were cut
into 4-μm sections and dried on capillary-gap glass
slides (DakoCytomation). The sections were deparaffi-
nized with standard xylene and hydrated through graded
alcohols into water. Antigen retrieval was performed by
heating 5 minutes in a pressure cooker with citrate buf-
fer (pH 6.0). Tissue slides were incubated overnight at
4°C in a humid chamber with mouse IgG anti-podopla-
nin monoclonal antibody (clone D2-40, Covance Inc.
formerly Signet Catalog No. 730-01) at 1:100 dilution
and staining was done by using the DakoCytomation
Envision Plus peroxidase mouse system and diamino-
benzidine chromogen as substrate (DakoCytomation).
Counterstaining with haematoxylin for 1 minute was
the final step. After staining, the slides were dehydrated
through graded alcohols and mounted with a cover slip
Rodrigo et al. Molecular Cancer 2010, 9:48
http://www.molecular-cancer.com/content/9/1/48
Page 2 of 9using a standard medium. Expression of podoplanin in
lymphatic endothelial cells within the stroma served as
an internal positive control. Negative controls with an
omission of the antiserum from the primary incubation
were also included. The slides were analysed randomly
by three of the authors, blinded to clinical data.
To allow for a comparison between the results from
this study and those previously reported [13,14], two dif-
ferent scoring systems were used to evaluate podoplanin
expression in laryngeal premalignant lesions and laryn-
geal carcinomas. In premalignant lesions, immunostain-
ing was scored using a similar scoring system to that
described by Kawaguchi et al [14], as follows: (0) if no
expression was observed in any part of the epithelium,
(1) expression restricted to the basal layer of the epithe-
lium, (2) expression in the basal and suprabasal layers at
one area, and (3) suprabasal layer expression at two or
more areas.
In laryngeal carcinomas, podoplanin expression was
scored as described by Yuan et al:[ 1 3 ] :q u a n t i t ys c o r e s
from 0 to 5 were respectively assigned if 0%, 1% to 10%,
11% to 30%, 31% to 50%, 51% to 80%, and 81% to 100%
of the tumour cells were positive. The staining intensity
was rated on a scale of 0 to 3 (0 = negative, 1 = weak,
2 = moderate, and 3 = strong). The raw data were then
converted to a German Immunoreactive Score (IRS) by
multiplying the quantity and staining intensity scores.
Theoretically, the scores could range from 0 to 15. An
IRS score above the median (7 or higher) was consid-
ered high reactivity and 0 to 6 weak. The consensus opi-
nions were used to assign final IRS scores to the
disputed cases before data analysis.
Statistical analyses
All statistical analyses were performed using the SPSS
statistical software version 8.0 (SPSS Inc., Chicago, IL.,
USA). The c
2 test or Fisher’s exact test were used for
comparison between categorical variables and Student’s
t-test for parametric continuous variables. Time-to-
event analyses were calculated using the Kaplan-Meier
product-limit estimate. Differences between times were
analysed by the log-rank method. Multivariate Cox pro-
portional hazards models were used to examine the rela-
tive impact of either variables demonstrated to be
statistically significant in univariate analysis or those
variables likely to have an effect on outcome. All tests
were two-sided. P values of ≤ 0.05 were considered sta-
tistically significant.
Results
Podoplanin expression during laryngeal tumourigenesis
Podoplanin expression was consistently detected with
high immunoreactivity in endothelial cells of lymphatic
vessels, as expected according to its established role as
lymphatic marker. In contrast, podoplanin expression in
normal laryngeal epithelium was negligible or restricted
to small clusters of cells within the basal layer that
showed mainly membranous and cytoplasmic staining
(Fig. 1A). Podoplanin expression in dysplastic laryngeal
epithelium was highly variable, from no expression (Fig.
1B) to high expression (Fig. 1C), yielding a predominant
membranous pattern at the basal layer. In some cases,
the expression extended to suprabasal layer or above at
one or multiple areas (Fig. 1C-1D).
Among the 84 dysplastic lesions analysed, 10 cases
(12%) showed no detectable podoplanin expression in
the epithelium (scored as 0), 37 (44%) showed podopla-
nin expression only in certain basal cells (scored as 1),
12 (14%) podoplanin expression extending to suprabasal
layer at one area (scored as 2), and 25 (30%) at two or
more areas (scored as 3), as illustrated in Figure 1.
According to the criteria previously described [13],
Table 1 Clinico-pathological characteristics of the
laryngeal squamous cell carcinomas and correlations
with podoplanin expression.
Parameter No (%) Low
podoplanin
expression (%)
High
podoplanin
expression (%)
P
Tumour site
- Supraglottis 23 (43) 19 (83) 4 (17) 0.01
- Glottis 30 (57) 14 (47) 16 (53)
pT classification
- T1 14 (26) 5 (36) 9 (64) 0.033
- T2 13 (25) 7 (54) 6 (46)
- T3 17 (32) 13 (76) 4 (24)
- T4 9 (17) 8 (89) 1 (11)
pN classification
- N0 38 (72) 23 (61) 15 (39) 0.53
- N1-3 15 (28) 10 (67) 5 (33)
Disease stage
- I 16 (30) 5 (31) 11 (69) 0.006
- II 9 (17) 5 (56) 4 (44)
- III 10 (19) 7 (70) 3 (30)
- IV 18 (34) 16 (89) 2 (11)
Degree of
differentiation
- Well
differentiated
32 (60) 16 (50) 16 (50) 0.04
- Moderately
differentiated
16 (30) 13 (81) 3 (19)
- Poorly
differentiated
5 (10) 4 (80) 1 (20)
Recurrence
- No recurrence 42 (79) 25 (60) 17 (40) 0.42
- Loco-regional
recurrence
7 (13) 4 (57) 3 (43)
- Distant
metastasis
4 (8) 4 (100) 0 (0)
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Page 3 of 9Figure 1 Immunohistochemical analysis of podoplanin expression. Representative examples of podoplanin expression in normal laryngeal
epithelium (A), dysplastic epithelium with negative podoplanin staining (B), dysplastic epithelium with positive podoplanin staining scored as 2
(C) and 3 (D), laryngeal carcinomas showing diffuse podoplanin expression (E) and focal expression (F).
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positive based on the notion that lesions with extensive
podoplanin expression beyond the basal layer may
reflect clonal expansion and are more prone to progres-
sion. Thus, 37 (44%) of the 84 lesions were classified as
podoplanin-positive and the remaining 47 (56%) lesions
were considered podoplanin-negative.
There was no statistically significant correlation
between podoplanin status and the severity of dysplasia:
5 (36%) of the 14 lesions with mild dysplasia, 9 (35%) of
the 26 lesions with moderate dysplasia, and 23 (52%) of
the 44 lesions with severe dysplasia/carcinoma “in situ”
exhibited positive podoplanin expression (P = 0.28).
The expression of podoplanin in the dysplastic lesions
was correlated with the risk of progression to laryngeal
cancer (Table 2). During the follow-up period, 33 of the
84 patients (39%) developed an invasive carcinoma at
the same site of the previous premalignant lesion. The
evolution to invasive carcinoma in relation to the histo-
pathological diagnosis iss h o w ni nT a b l e2 .I nt h i s
cohort study, the group of patients with mild dysplasia
showed the highest rate of progression to malignancy
although the differences were not statistically significant.
The mean time to cancer diagnosis in the cases that
progressed was 28 months (range 11 to 66 months).
The risk for laryngeal cancer development in patients
whose lesions scored 0 or 1 seems lower than in those
whose lesions scored 2 or 3, especially after the first 3
years of follow-up (Fig. 2A). Consistent with these
results, patients with podoplanin-positive lesions had a
higher laryngeal cancer incidence than did those with
podoplanin-negative lesions (Fig. 2B), although the dif-
ferences did not reach statistical significance (HR =
1.84; 95%CI, 0.92-3.68; P = 0.076). At 5 years after the
patients were diagnosed, 30% of the patients with nega-
tive podoplanin expression developed laryngeal cancer
compared with 51% of the patients with positive podo-
planin expression (P = 0.071; Table 2).
Podoplanin expression in laryngeal squamous
cell carcinomas
As expected podoplanin was highly expressed in lym-
phatic endothelial cells, whereas in histologically normal
squamous epithelium adjacent to the tumours podopla-
nin expression was not detectable or extremely low in
some basal cells. In laryngeal carcinomas, podoplanin
expression was generally heterogeneous and exhibited
two different patterns, similar to previous observations
in oral cancer [12]: 20 (38%) cases showed diffuse
expression in most tumour cells (Fig. 1E) and 33 (62%)
cases showed focal expression at the proliferating
Table 2 Evolution of the premalignant lesions in relation
to histopathological diagnosis and podoplanin
expression
Characteristic No. of
cases
Progression to
carcinoma (%)
P
Histopathological diagnosis
- Mild dysplasia 14 7 (50) 0.27
- Moderate dysplasia 26 7 (27)
- Severe dysplasia 44 19 (43)
Podoplanin expression
- Negative (scores 0-1) 47 14 (30) 0.071
- Positive (scores 2-3) 37 19 (51)
Figure 2 Kaplan-Meier cancer-free survival curves categorized by podoplanin scores (A), and by podoplanin expression (positive
versus negative) (B). P values were estimated using the log-rank test.
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the central areas (Fig. 1F). In the latter cases the central
areas often contained more differentiated cells, mimick-
ing the pattern seen in the dysplastic epithelium. Two
(4%) of the tumours showed no podoplanin expression,
31 (58%) had weak or moderate expression (IRS scores
1-6), and 20 (38%) had high expression (scores 7-15).
For statistical purposes, tumours with scores equal or
lower than 6 (median value) were considered to have
low podoplanin expression, whereas those with scores
higher than 6 were considered high expression.
The relationships between podoplanin expression and
the clinico-pathological variables are shown in Table 1.
Higher levels of podoplanin expression were observed in
glottic carcinomas (P = 0.01). Podoplanin expression sig-
nificantly decreased as T classification increased (P =
0.033) and in consequence there was also a significant
inverse association of podoplanin expression with dis-
ease stage (P = 0.006), with most stage IV tumours
showing low podoplanin expression. Moreover, well-dif-
ferentiated carcinomas exhibited significantly higher
levels of podoplanin, compared to moderately or poorly
differentiated carcinomas (P =0 . 0 4 ) .N oc o r r e l a t i o n
between podoplanin expression and nodal metastasis
was observed (P = 0.53).
Patients were followed-up for a minimum of 36
months. The median follow-up of the whole series was
36 months (range, 4-84 months), and the median fol-
low-up of the patients alive at the last visit was 43
months (range, 36-84 months). During this follow-up
period, seven (13%) cases developed loco-regional
recurrence, and 4 (8%) cases distant metastasis. Podo-
planin expression was not associated with tumour
recurrence (P = 0.42, Table 1) and no significant dif-
ferences in overall survival were observed when com-
paring patients with high versus low podoplanin
expression (Log-rank test, P = 0.66; Fig 3A). Neverthe-
less, patients with low levels of podoplanin had a
poorer disease-specific survival, although this differ-
ence did not reach significance (Log-rank Test, P =
0.31; Fig. 3B). Furthermore, those cases showing dif-
fuse podoplanin staining had a poorer disease specific-
survival than the cases that displayed a focal expres-
sion pattern in the periphery of tumour nests, but
there was only a borderline statistical difference (Log-
rank test, P = 0.08; Fig 3C).
Multivariate analysis using the Cox proportional
hazards model included tumour site, T classification,
nodal metastasis, stage, and degree of differentiation and
podoplanin expression. This model showed that only the
presence of cervical lymph node metastasis was a signifi-
cant independent predictor of reduced disease-specific
Figure 3 Kaplan-Meier overall (A) and disease-free survival (B)
curves categorized by podoplanin expression (high versus low)
and disease-free survival (C) by podoplanin expression pattern
(focal versus diffuse). P values were estimated using the log-rank
test.
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survival (HR = 6; 95%CI, 2.3-15.6; P = 0.0002).
Discussion
The physiological function of podoplanin is still
unknown. Podoplanin-deficient mice die at birth owing
to respiratory failure exhibiting a phenotype of dilated,
malfunctioning lymphatic vessels and lymphoedema
[16]. In addition, podoplanin can induce platelet aggre-
gation in vitro [17]. In the pathological situations stu-
died thus far, the mouse homologue of podoplanin
(PA2.26, OTS-8) is induced in mouse skin during tissue
regeneration after wounding and treatment with carci-
nogenic phorbol 12-myristate 13-acetate [18]. OTS-8 is
also induced by 12-Otetradecanoylphorbol- 13-acetate
in mouse osteoblastic cells and is constitutively
expressed in oncogenic Ras-transformed cells [19].
Podoplanin has also been found to promote tumour cell
invasion by inducing collective cell migration via the
down-regulation of the activities of small Rho family
GTPases [20]. These findings suggest a role of podopla-
nin in tissue development and repair as well as in carci-
nogenesis and malignant progression.
In this study we found that podoplanin is expressed in
a high percentage of dysplastic lesions and squamous
cell carcinomas of the larynx. This is not surprising
since podoplanin expression is mainly detected in squa-
mous cell cancers, CNS tumours and germinal neopla-
sia; in contrast, expression of podoplanin has not been
found in the majority of adenocarcinomas, including
lung, colon and prostate cancers [20]. Podoplanin
expression has been previously explored in other head
and neck squamous cell carcinomas, such as oral and
hypopharyngeal carcinomas [13], as well as in oral pre-
malignancies [14]. However, our study is the first to
analyse podoplanin expression in both laryngeal prema-
lignant lesions and laryngeal carcinomas and its rela-
tionship with clinico-pathological parameters and
prognosis.
In oral leukoplakia, high podoplanin expression has
been associated with an increased risk of progression to
invasive cancer, suggesting that podoplanin could serve
as a powerful biomarker to predict the risk for oral can-
cer development in patients with oral leukoplakia [14].
This evidence supports the importance of podoplanin in
oral tumourigenesis and malignant transformation. Simi-
larly, our findings indicate that podoplanin is also fre-
quently abnormally expressed in the early stages of
laryngeal tumourigenesis and patients carrying podopla-
nin-positive dysplastic lesions (scores 2-3) exhibit a
higher incidence of laryngeal cancer than patients with
negative expression (51% versus 30%), although these
differences did not reach statistical significance (P =
0.071). Since podoplanin expression was not associated
with the severity of dysplasia, this trend towards a
poorer prognosis for patients with podoplanin-positive
dysplasias suggests a role for podoplanin in the progres-
sion to laryngeal cancer. In this study cohort, the histol-
ogy of the lesions does not have a significant role in
assessing laryngeal cancer risk, and podoplanin seems a
stronger predictor. The unexpected high proportion of
mild dysplasias with progression to laryngeal carcinoma
in our cohort could be due to pure chance, given the
limited number of patients with this diagnosis. However,
this also underscores the limited value of histopathologi-
cal classification in predicting outcome. These data sug-
gest the utility of podoplanin as a biomarker for cancer
risk assessment providing additional value beyond cur-
rent clinical and histopathological evaluations.
Nevertheless, podoplanin expression alone may not be
sufficient to promote tumourigenesis because many of
the lesions (44%) exhibit protein expression only in the
basal layer cells, and this was independent of the sever-
ity of the dysplasia. Other factors are therefore needed
to promote clonal expansion of the abnormal cells. The
upward clonal expansion of the podoplanin-expressing
cells in the epithelial layers supports this notion. Indeed,
lesions with such clonal expansion carry a higher risk of
laryngeal cancer development. The ability to detect the
cells expanding beyond basal layers may allow us to
visualise potential clonal expansion, possibly from stem-
cell clones, during tumourigenesis [14]. In fact, podopla-
nin has been identified as a marker of tumour-initiating
cells (TICs) in squamous cell carcinomas [21]. Tumouri-
genicity and capability of recapitulating human SCC are
by definition properties of TICs. Premalignant lesions
with podoplanin expression beyond the basal cell layer
may represent truly early neoplastic lesions, enriched in
TICs and with a higher risk of progression to invasive
cancer.
In relation to the possible role of podoplanin in
tumour progression, it has been reported that high
podoplanin expression significantly associates with nodal
metastasis and reduced survival in oral squamous cell
carcinomas [13]. In marked contrast to these findings,
we did not find a significant association of podoplanin
expression with lymph node metastasis nor poor prog-
nosis in laryngeal cancer. On the contrary, patients with
high podoplanin expression showed a better disease-spe-
cific survival. This could be explained by the fact that
podoplanin expression was higher in early-stage
tumours and, interestingly, all cases that developed dis-
tant metastasis showed low podoplanin expression.
Indeed, we found a significant inverse association of
podoplanin expression with disease stage and T classifi-
cation. Podoplanin expression was also significantly
more frequent in glottic tumours, which are generally
smaller and detected at an earlier stage than supraglottic
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sion levels decreased with primary tumour size evidence
a higher proportion of podoplanin-positive cells in small
tumours and podoplanin-positive staining in those
tumours could reflect a higher proportion of TICs,
rather than a higher invasive potential. In addition,
podoplanin expression was also significantly higher in
well-differentiated tumours, which are usually less inva-
sive than those poorly differentiated. We also observed a
trend towards better disease-specific survival for patients
with a focal expression of podoplanin in the periphery
of tumour nests, defined in some works as the invasive
edge of the tumours [20]. There are contradictory data
regarding the clinical significance and biological role of
podoplanin expression in squamous cancers, with con-
trasting results depending on the tumour sites studied.
Thus, in squamous cell carcinoma of the uterine cervix,
low levels of podoplanin were significantly associated
with the presence of lymphatic invasion and lymph
node metastasis, as well as with shorter survival and
higher risk of tumour recurrence [22,23]. In addition,
tumour emboli within lymphatic spaces as well as meta-
static cells from lymph nodes showed no podoplanin
immunostaining in the vast majority of tumours, even in
those cases with positive expression in the main tumour
mass [23]. In squamous cell carcinomas of the lung [24],
patients who had podoplanin-positive tumours, and
especially those with focal expression in the periphery of
tumour nests (named hierarchical distribution pattern
by the authors) showed a significantly better overall sur-
vival than those with podoplanin-negative tumours. In
addition, podoplanin expression in these tumours inver-
sely correlated with lymphatic invasion and lymph node
metastasis. This is in marked contrast to the observa-
tions made by Yuan et al [13] in oral squamous cell car-
cinomas, although in good agreement with the results
presented herein. The results presented by Shimada
et al [24] and our results suggest that squamous cell
carcinomas with focal expres s i o no fp o d o p l a n i ni nt h e
periphery of tumour nests (which is equivalent to the
hierarchical distribution pattern) may indicate lower bio-
logical aggressiveness. According to this, it is plausible
that squamous cell carcinomas showing focal expression
pattern represent a well-organised tumour group based
on the TICs concept, whereas squamous cell carcinomas
with a diffuse expression pattern could reflect disor-
dered tumours in terms of the developmental hierarchy.
Hence the role of podoplanin in tumour initiation and
progression remains elusive. Its involvement in tumour
metastasis, however, has been demonstrated in an
experimental model to be due to its platelet aggrega-
tion-inducing activity leading to pulmonary retention of
CHO cells that overexpress podoplanin [25]. It has also
been demonstrated that podoplanin contributes to
tumour invasion by binding ERM proteins to activate
RhoA resulting in epithelial-mesenchymal transition
[26]. Although podoplanin-positive TICs in squamous
cell carcinomas may use these mechanisms to initiate
and sustain tumour growth, they may also proliferate
rapidly through the activation of the SHH signalling
pathway [21]. In addition to these intrinsic mechanisms,
the microenvironment also influences the ability of TICs
to generate tumours [21]. Considering their localization,
it has been proposed that TICs may be regulated by
stromal cells, which is comparable to the regulation of
stem cells by their environmental niche [21]. Histologi-
cally, podoplanin-positive cells were specifically located
in most cases at the basal region of squamous cell carci-
noma tumour nests, close to the surrounding stromal
cells and the tumour-microenvironment interaction
plays a decisive role in cancer progression. It has been
recently described that positive podoplanin expression
in stromal fibroblasts exerts a protective role against cell
invasion and is a significant indicator of good prognosis
in patients with advanced colorectal cancer [27].
Conclusions
We have demonstrated for the first time that podopla-
nin is expressed in a high percentage of laryngeal dys-
plasias and laryngeal squamous cell carcinomas.
Podoplanin-positive dysplasias had a higher risk of pro-
gression to invasive carcinoma than those with negative
expression, although the differences did not reach statis-
tical significance. Prospective studies involving larger
numbers of patients are needed to further evaluate the
clinical utility of podoplanin as a biomarker for laryngeal
cancer risk assessment providing additional value
beyond the clinical and histological markers. Podoplanin
expression in laryngeal squamous cell carcinomas, how-
ever, diminishes during tumour progression and does
not correlate with invasive potential. Taken together,
these data support a role for podoplanin expression in
the initiation rather than in the progression of laryngeal
cancers.
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